Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer

Ayca Gucalp, Joseph A. Sparano, James Caravelli, Jean Santamauro, Sujata Patil, Alyson Abbruzzi, Christine Pellegrino, Jackie Bromberg, Chau Dang, Maria Theodoulou, Joan Massague, Larry Norton, Clifford Hudis, Tiffany A. Traina

Research output: Contribution to journalArticle

79 Citations (Scopus)

Abstract

Saracatinib is an oral, tyrosine kinase inhibitor selective for Src. This was a nonrandomized, open-label, phase II trial to evaluate the efficacy/safety of saracatinib monotherapy in patients with estrogen receptor (ER)-and progesterone receptor (PR)-negative, metastatic breast cancer (MBC). Nine patients were treated on study before the trial was closed to accrual at the investigators' request, based on the observed risk: benefit ratio. Based on this series, saracatinib does not appear to have significant single-agent activity for the treatment of patients with ER(-)/ PR(-) MBC. Background: SRC activation is associated with cell migration, proliferation, and metastasis. Saracatinib is an oral tyrosine kinase inhibitor (TKI) selective for SRC. We performed this trial to evaluate the efficacy and safety of saracatinib monotherapy in patients with estrogen receptor (ER)-and progesterone receptor (PR)-metastatic breast cancer (MBC). Patients and Methods: Patients who had undergone ≤ 1 previous chemotherapy regimen for measurable ER-and PR-MBC received saracatinib 175 mg orally daily. The primary endpoint was disease control defined as complete response (CR) + partial response (PR) + stable disease (SD) > 6 months. Secondary endpoints included toxicity and progression-free survival (PFS). Levels of circulating tumor cells (CTCs) in response to therapy were measured over time. Results: Nine patients were treated on study. After a median of 2 cycles (range 1-3), no patient had achieved CR, PR, or SD >6 months. The median time to treatment failure was 82 days (12-109 days).The majority (89%) of patients discontinued saracatinib because of disease progression. One patient acquired potentially treatment-related grade 4 hypoxia with interstitial infiltrates and was removed from the study. Common adverse events included fatigue, elevated liver enzymes, nausea, hyponatremia, dyspnea, cough, and adrenal insufficiency. Conclusions: These efficacy results were not sufficiently promising to justify continued accrual to this study. Based on this series, saracatinib does not appear to have significant single-agent activity for the treatment of patients with ER-/PR-MBC.

Original languageEnglish (US)
Pages (from-to)306-311
Number of pages6
JournalClinical Breast Cancer
Volume11
Issue number5
DOIs
StatePublished - 2011

Fingerprint

Hormones
Breast Neoplasms
Progesterone Receptors
Estrogen Receptors
Therapeutics
Protein-Tyrosine Kinases
saracatinib
Circulating Neoplastic Cells
Safety
Adrenal Insufficiency
Hyponatremia
Treatment Failure
Cough
Dyspnea
Nausea
Disease-Free Survival
Cell Movement
Fatigue
Disease Progression
Odds Ratio

Keywords

  • Hormone receptor (HR)-negative breast cancer
  • Pulmonary toxicity
  • Saracatinib
  • SRC-inhibitor

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer. / Gucalp, Ayca; Sparano, Joseph A.; Caravelli, James; Santamauro, Jean; Patil, Sujata; Abbruzzi, Alyson; Pellegrino, Christine; Bromberg, Jackie; Dang, Chau; Theodoulou, Maria; Massague, Joan; Norton, Larry; Hudis, Clifford; Traina, Tiffany A.

In: Clinical Breast Cancer, Vol. 11, No. 5, 2011, p. 306-311.

Research output: Contribution to journalArticle

Gucalp, A, Sparano, JA, Caravelli, J, Santamauro, J, Patil, S, Abbruzzi, A, Pellegrino, C, Bromberg, J, Dang, C, Theodoulou, M, Massague, J, Norton, L, Hudis, C & Traina, TA 2011, 'Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer', Clinical Breast Cancer, vol. 11, no. 5, pp. 306-311. https://doi.org/10.1016/j.clbc.2011.03.021
Gucalp, Ayca ; Sparano, Joseph A. ; Caravelli, James ; Santamauro, Jean ; Patil, Sujata ; Abbruzzi, Alyson ; Pellegrino, Christine ; Bromberg, Jackie ; Dang, Chau ; Theodoulou, Maria ; Massague, Joan ; Norton, Larry ; Hudis, Clifford ; Traina, Tiffany A. / Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer. In: Clinical Breast Cancer. 2011 ; Vol. 11, No. 5. pp. 306-311.
@article{51bc7386373f4bb0b6cfd46a10a477cd,
title = "Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer",
abstract = "Saracatinib is an oral, tyrosine kinase inhibitor selective for Src. This was a nonrandomized, open-label, phase II trial to evaluate the efficacy/safety of saracatinib monotherapy in patients with estrogen receptor (ER)-and progesterone receptor (PR)-negative, metastatic breast cancer (MBC). Nine patients were treated on study before the trial was closed to accrual at the investigators' request, based on the observed risk: benefit ratio. Based on this series, saracatinib does not appear to have significant single-agent activity for the treatment of patients with ER(-)/ PR(-) MBC. Background: SRC activation is associated with cell migration, proliferation, and metastasis. Saracatinib is an oral tyrosine kinase inhibitor (TKI) selective for SRC. We performed this trial to evaluate the efficacy and safety of saracatinib monotherapy in patients with estrogen receptor (ER)-and progesterone receptor (PR)-metastatic breast cancer (MBC). Patients and Methods: Patients who had undergone ≤ 1 previous chemotherapy regimen for measurable ER-and PR-MBC received saracatinib 175 mg orally daily. The primary endpoint was disease control defined as complete response (CR) + partial response (PR) + stable disease (SD) > 6 months. Secondary endpoints included toxicity and progression-free survival (PFS). Levels of circulating tumor cells (CTCs) in response to therapy were measured over time. Results: Nine patients were treated on study. After a median of 2 cycles (range 1-3), no patient had achieved CR, PR, or SD >6 months. The median time to treatment failure was 82 days (12-109 days).The majority (89{\%}) of patients discontinued saracatinib because of disease progression. One patient acquired potentially treatment-related grade 4 hypoxia with interstitial infiltrates and was removed from the study. Common adverse events included fatigue, elevated liver enzymes, nausea, hyponatremia, dyspnea, cough, and adrenal insufficiency. Conclusions: These efficacy results were not sufficiently promising to justify continued accrual to this study. Based on this series, saracatinib does not appear to have significant single-agent activity for the treatment of patients with ER-/PR-MBC.",
keywords = "Hormone receptor (HR)-negative breast cancer, Pulmonary toxicity, Saracatinib, SRC-inhibitor",
author = "Ayca Gucalp and Sparano, {Joseph A.} and James Caravelli and Jean Santamauro and Sujata Patil and Alyson Abbruzzi and Christine Pellegrino and Jackie Bromberg and Chau Dang and Maria Theodoulou and Joan Massague and Larry Norton and Clifford Hudis and Traina, {Tiffany A.}",
year = "2011",
doi = "10.1016/j.clbc.2011.03.021",
language = "English (US)",
volume = "11",
pages = "306--311",
journal = "Clinical Breast Cancer",
issn = "1526-8209",
publisher = "Elsevier",
number = "5",

}

TY - JOUR

T1 - Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer

AU - Gucalp, Ayca

AU - Sparano, Joseph A.

AU - Caravelli, James

AU - Santamauro, Jean

AU - Patil, Sujata

AU - Abbruzzi, Alyson

AU - Pellegrino, Christine

AU - Bromberg, Jackie

AU - Dang, Chau

AU - Theodoulou, Maria

AU - Massague, Joan

AU - Norton, Larry

AU - Hudis, Clifford

AU - Traina, Tiffany A.

PY - 2011

Y1 - 2011

N2 - Saracatinib is an oral, tyrosine kinase inhibitor selective for Src. This was a nonrandomized, open-label, phase II trial to evaluate the efficacy/safety of saracatinib monotherapy in patients with estrogen receptor (ER)-and progesterone receptor (PR)-negative, metastatic breast cancer (MBC). Nine patients were treated on study before the trial was closed to accrual at the investigators' request, based on the observed risk: benefit ratio. Based on this series, saracatinib does not appear to have significant single-agent activity for the treatment of patients with ER(-)/ PR(-) MBC. Background: SRC activation is associated with cell migration, proliferation, and metastasis. Saracatinib is an oral tyrosine kinase inhibitor (TKI) selective for SRC. We performed this trial to evaluate the efficacy and safety of saracatinib monotherapy in patients with estrogen receptor (ER)-and progesterone receptor (PR)-metastatic breast cancer (MBC). Patients and Methods: Patients who had undergone ≤ 1 previous chemotherapy regimen for measurable ER-and PR-MBC received saracatinib 175 mg orally daily. The primary endpoint was disease control defined as complete response (CR) + partial response (PR) + stable disease (SD) > 6 months. Secondary endpoints included toxicity and progression-free survival (PFS). Levels of circulating tumor cells (CTCs) in response to therapy were measured over time. Results: Nine patients were treated on study. After a median of 2 cycles (range 1-3), no patient had achieved CR, PR, or SD >6 months. The median time to treatment failure was 82 days (12-109 days).The majority (89%) of patients discontinued saracatinib because of disease progression. One patient acquired potentially treatment-related grade 4 hypoxia with interstitial infiltrates and was removed from the study. Common adverse events included fatigue, elevated liver enzymes, nausea, hyponatremia, dyspnea, cough, and adrenal insufficiency. Conclusions: These efficacy results were not sufficiently promising to justify continued accrual to this study. Based on this series, saracatinib does not appear to have significant single-agent activity for the treatment of patients with ER-/PR-MBC.

AB - Saracatinib is an oral, tyrosine kinase inhibitor selective for Src. This was a nonrandomized, open-label, phase II trial to evaluate the efficacy/safety of saracatinib monotherapy in patients with estrogen receptor (ER)-and progesterone receptor (PR)-negative, metastatic breast cancer (MBC). Nine patients were treated on study before the trial was closed to accrual at the investigators' request, based on the observed risk: benefit ratio. Based on this series, saracatinib does not appear to have significant single-agent activity for the treatment of patients with ER(-)/ PR(-) MBC. Background: SRC activation is associated with cell migration, proliferation, and metastasis. Saracatinib is an oral tyrosine kinase inhibitor (TKI) selective for SRC. We performed this trial to evaluate the efficacy and safety of saracatinib monotherapy in patients with estrogen receptor (ER)-and progesterone receptor (PR)-metastatic breast cancer (MBC). Patients and Methods: Patients who had undergone ≤ 1 previous chemotherapy regimen for measurable ER-and PR-MBC received saracatinib 175 mg orally daily. The primary endpoint was disease control defined as complete response (CR) + partial response (PR) + stable disease (SD) > 6 months. Secondary endpoints included toxicity and progression-free survival (PFS). Levels of circulating tumor cells (CTCs) in response to therapy were measured over time. Results: Nine patients were treated on study. After a median of 2 cycles (range 1-3), no patient had achieved CR, PR, or SD >6 months. The median time to treatment failure was 82 days (12-109 days).The majority (89%) of patients discontinued saracatinib because of disease progression. One patient acquired potentially treatment-related grade 4 hypoxia with interstitial infiltrates and was removed from the study. Common adverse events included fatigue, elevated liver enzymes, nausea, hyponatremia, dyspnea, cough, and adrenal insufficiency. Conclusions: These efficacy results were not sufficiently promising to justify continued accrual to this study. Based on this series, saracatinib does not appear to have significant single-agent activity for the treatment of patients with ER-/PR-MBC.

KW - Hormone receptor (HR)-negative breast cancer

KW - Pulmonary toxicity

KW - Saracatinib

KW - SRC-inhibitor

UR - http://www.scopus.com/inward/record.url?scp=84855748821&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855748821&partnerID=8YFLogxK

U2 - 10.1016/j.clbc.2011.03.021

DO - 10.1016/j.clbc.2011.03.021

M3 - Article

C2 - 21729667

AN - SCOPUS:84855748821

VL - 11

SP - 306

EP - 311

JO - Clinical Breast Cancer

JF - Clinical Breast Cancer

SN - 1526-8209

IS - 5

ER -